Aug 04, 2022 7:05am EDT Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
Jun 01, 2022 7:05am EDT Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia
May 12, 2022 7:05am EDT Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 7:05am EDT Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
Apr 28, 2022 7:05am EDT Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia
Mar 17, 2022 7:05am EDT Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 10, 2022 7:05am EST Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022
Mar 08, 2022 4:05pm EST Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022
Feb 28, 2022 7:05am EST Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID
Jan 04, 2022 4:05pm EST Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference
